Hello! Welcome to the official website of Betta Pharmaceuticals!
Service Hotline:0571-86130357     Add to Favorites | Online Feedback 中文
新闻中心 / News Center
Class 1.1 New Drug of Betta Pharmaceuticals BPI-9016M Obtaining the Approval Document of Clinical Trial
Form: Betta Pharmaceuticals   Date: 2015-04-02

    On March 15th, 2015, national Class 1.1 targeted small-molecule anti-cancer new drug, BPI-9016M, obtained the Clinical Trial Approval Document, issued by CFDA, for Phase I/II/III clinical trials.

    BPI-9016M is a candidate pharmaceutical molecule obtained based on computer simulation design and rounds of screening and structural optimization. It is a small-molecule TKI with the independent IPR and brand-new chemical structure. Pre-clinical research results have shown that BPI-9016M is featured by a significant anti-tumor activity and a sound safety.

    BPI-9016M is novel in the selection of target. Its successful launching on the market will provide a new choice for cancer treatment and bring a sound social benefit. This project has been supported by National Key New-drug Special Project.

    Betta Pharmaceuticals Winning the 16th Session of Golden Award of China Patent Award

 

Prev: Chinese and English Trademark of Conmana Rated as Famous Trademarks of Zhejiang Province
Next: The company’s patent won the gold medal of the 16th WIPO-SIPO Award for Chinese Outstanding Patented Invention & Industrial Design